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Stem cells are defined as precursor cells that have the
capacity to self-renew and to generate multiple mature
cell types. Only after collecting and culturing tissues is it
possible to classify cells according to this operational
concept. This difficulty in identifying stem cells in situ,
without any manipulation, limits the understanding of
their true nature. This review aims at presenting, to health
professionals interested in this area, an overview on the
biology of embryonic and adult stem cells, and their
therapeutic potential.
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Although the initial concept of stem cells is more than 100
years old,1 and much of its biology and therapeutic potential
has been explored in the past three decades, we still know
little about their true nature. This review is intended to
provide an overview on the biology of stem cells and their
therapeutic potential to those interested in this field.
Stem cells are operationally defined as cells that have the
potential for unlimited or prolonged self-renewal, as well as the
ability to give rise to at least one type of mature, differentiated
cells.2,3 Although this basic definition of ‘stemness’ applies
generally to stem cells, it is necessary to individually consider
embryonic and adult stem cells as they do not share much
more than the name and the basic definition above.
EMBRYONIC STEM CELLS
In humans, the embryo is defined as the organism from the
time of implantation in the uterus until the end of the second
month of gestation. Embryonic stem cells (ESCs), however,
refer to a much more restricted period, resulting from the
isolation and cultivation of cells from the blastocyst, which
forms at approximately 5 days after fertilization.4
Establishing ESC lines
The zygote, which is the cell resulting from the fertilization of
an oocyte by a spermatozoon, is totipotent. Several successive
cell divisions generate the morula, with 32–64 totipotent cells.
After that stage, it develops into the blastocyst, which consists
of a hollow ball of cells. Peripheral cells (the trophoblast) of
the blastocyst generate the embryonic membranes and
placenta, whereas the inner cell mass develops into the fetus.
These are the cells that are used to establish stem cell cultures
(Figure 1). They are not totipotent, as they do not have the
ability to support the formation of another embryo, and are
considered to be pluripotent as they can produce all the cell
types of the adult organism. Further development of the
embryo leads to the formation of the gastrula, composed of
the three germ layers (ectoderm, mesoderm, and endoderm),
from which the complete organism develops.
In 1981, two groups established the first ESC lines from
mouse blastocysts, and in 1998 the first human ESC line
was generated.5 Although seemingly simple, the procedure
is technically demanding because of the need for strictly
controlled conditions necessary for the maintenance of
the cells in the undifferentiated state. This is particularly
important for human ESCs.6 Once established, ESC lines may
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be maintained in permanent culture, frozen and thawed, and
transported between laboratories. It is estimated that there
are currently around 250 human ESC lines in the world,
widely shared among different groups. The process of
establishing an ESC line requires, however, the destruction
of the blastocyst, raising ethical issues as scientific investiga-
tion alone is not capable of determining whether blastocysts
constitute human beings. An alternative method involves the
production of ESCs by collection of only one cell from the
inner cell mass, allowing implantation of the remaining cells
in the womb. However, ethical considerations still remain as
it has to be tested whether the remaining cells can develop
into a normal human being.
Characteristics of ESCs
Cultured ESCs show defined characteristics: they are
pluripotent, capable of differentiating into cells derived from
all three germ layers; they are immortal in culture and may be
maintained for several hundred passages in the undiffer-
entiated state; and they maintain a normal chromosomal
composition.
Molecular characterization of ESCs is well developed, and
they are known to express surface markers such as CD9,
CD24, and alkaline phosphatase, and several genes involved
with pluripotency, including Oct-4, Rex-1, SOX-2, Nanog,
LIN28, Thy-1, and SSEA-3 and -4.7 Expression of high levels
of telomerase explains their immortality in culture.
ESC research focuses mainly on two issues, both of
which have shown significant progress in the past few years.6
The first point explores how to better maintain the cells in
long-term culture, without significant modifications of
their genetic composition and, in the case of human ESCs,
avoiding the need for animal products in the culture.
Generally, the cells are maintained in culture on feeder cells
such as mouse fibroblasts. The second point focuses on how
to differentiate the cells into the many mature cell types that
are necessary for the potential treatment of different diseases.
ESCs can be induced to differentiate into various cell types
in suspension culture, resulting in three-dimensional cell
aggregates called embryoid bodies. This tendency of ESCs
to differentiate spontaneously may not always be desirable.
A technical challenge is to control the differentiation process:
although the addition of growth factors directs the differen-
tiation process, usually the cultures spontaneously differen-
tiate into various cell types. It is thus necessary to use
methods that allow removal of undifferentiated ESCs from
cultures in which the differentiated cell types are the desired
product.
Induced pluripotent stem cells
Recently, methods for direct reprogramming of adult cells to
induced pluripotent stem cells have been developed.8 In the
process, mature cells from the patient are treated in vitro with
genes that ‘dedifferentiate’ them to a pluripotent stage,
similar to an ESC (Figure 2). Induced pluripotent stem cells
are believed to be identical to natural pluripotent ESCs in
many respects, including the expression of specific genes and
proteins, chromatin methylation patterns, culture kinetics,
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Figure 1 | Embryonic stem cell cultivation. The zygote
undergoes successive mitotic divisions until a sphere of cells—the
blastocyst—is formed. In the blastocyst, the trophoblast at its
periphery generates the embryonic membranes and placenta,
whereas the inner cell mass develops into the fetus. Embryonic
stem cells are immortal in culture, having been established from
one pluripotent cell collected from the inner cell mass. These are
capable of differentiating into any of the mature cell types
present in the adult organism.
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Figure 2 |Production of induced pluripotent stem (iPS) cells.
iPS cells are produced by treating mature cells, such as fibroblasts,
with genes that ‘dedifferentiate’ them to a pluripotent stage,
similar to an embryonic stem cell. Viral vectors, such as
retroviruses, are generally used for gene transfer. The transformed
cells become morphologically and biochemically similar to
pluripotent stem cells, with the advantage of representing
autologous cells in therapeutic applications.
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in vitro differentiation patterns, and teratoma formation.
Besides avoiding the ethical issues associated with the
destruction of human embryos, this approach allows the
generation of patient-specific cells of any lineage. Problems
related to the genetic modification of target cells, however,
must still be resolved before induced pluripotent stem cells
may be clinically tested.
Therapeutic potential of ESCs
The principal advantage of ESCs over adult stem cells is
related to their pluripotency and limitless expansion in
culture, as they have the potential to give rise to all cell types
composing the adult organism. This potential is exploited in
vitro to develop specialized cells that are then used in therapy.
Owing mainly to safety issues, the clinical use of hESCs is
much more restricted than that of adult stem cells. As proof
of pluripotency, ESC lineages injected into immunodeficient
mice must lead to teratoma formation, with derivatives of
all three germ layers. Only differentiated cells derived from
ESCs may be administered to patients, as any contaminating
undifferentiated cells could give rise to cancer. The first
clinical trial using human ESC-derived cells, which in this
case are oligodendrocyte progenitor cells, was started in
October 2010. Care must be taken, however, to not call this
procedure ‘human ESC therapy’, as the cells to be used are no
longer ESCs.
ADULT STEM CELLS
Adult or somatic stem cells (ASCs) are rare, quiescent cells
with a more limited self-renewal and differentiation capacity.
Numerous types of precursor cells have been isolated in adult
tissues, leading to the concept that all tissues have their own
compartment of stem cells (Figure 3). They are responsible
for replenishing cells that die within a given organ, either due
to physiological (wear and tear) or pathological processes.
Types of adult stem cells
For some of the body compartments, including hematopoie-
tic, epithelial, muscular, and neural, the biological character-
istics of their intrinsic stem cells are better defined.9
Hematopoietic stem cells have been in clinical use for more
than 40 years, in bone marrow and more recently cord
blood transplantation. Mesenchymal stem cells (MSCs) are of
stromal origin and may be isolated from virtually any tissue
in the organism, which suggests a perivascular niche for this
population.10,11 MSCs are attractive for clinical therapy because
of their easy in vitro expansion and their ability to differentiate
into a variety of tissues, provision of trophic support, and
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Figure 3 |Adult or somatic stem cells (ASCs). ASCs are present in all types of organs and tissues in the organism, exemplified here by
neuronal stem cells in the subventricular zone of the brain, epithelial stem cells, and hematopoietic stem cells in the bone marrow. They are
responsible for replenishing cells that die, either in physiological (wear and tear) or pathological processes.
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modulation of immune responses.12 Even organs previously
considered as post-mitotic, such as the heart or kidney, are
now believed to have their own stem cell compartments, which
are, however, still poorly understood.13,14
Adult tissue-specific stem cells are rare and generally do
not display characteristic morphology or surface markers that
would readily distinguish them from mature cells. They can
therefore not be readily ‘isolated’ from any given tissue, but
a variety of protocols have succeeded to enrich stem/
progenitor cells to different degrees of purity. Human
hematopoietic stem cells, for instance, are usually collected
from the bone marrow or cord blood as CD34- or CD133-
positive, CD38- and lineage-negative populations. Even so, the
enriched fraction contains other cell types, and hematopoietic
stem cells are also present in the cell marker ‘negative’
population. The study of ASCs may be classified as basic, when
molecular or cellular aspects are investigated; preclinical, when
cell therapy protocols are tested in animal models; or as
clinical studies, when they are used to treat patients.
Maintenance of adult stem cells in the organism
ASCs are capable of long-term self-renewal and of giving rise
to mature cell types with specialized functions, reflecting
their ability of asymmetric division. Whereas one remains
as a self-renewing stem cell, the second daughter cell is
committed to replicating and differentiating into a mature
cell type (Figure 4). In this case, the cells generated are called
precursor or progenitor cells, which, after several rounds
of mitosis, give rise to differentiated cells.
The mechanisms controlling the fate of stem cells are not
fully understood, but they strongly depend on the interaction
between these cells and their microenvironment or niche.
Niches are composed of other cells, extracellular matrix, and
signaling factors, which, in combination with intrinsic
characteristics of stem cells, define their properties and
potential.15 The importance of the niche is becoming
increasingly clear, as stemness is maintained only when the
cells are attached to it (Figure 4). When ASCs leave the niche,
they enter a pathway of proliferation and differentiation.
Only by understanding this relationship and reproducing
the niche during in vitro culture willwe be able to expand
adult stem cells. The therapeutic use of ASCs also depends on
the understanding of this interrelationship, as ACSs must
recognize a ‘regenerative niche’ at the site of the lesion, home
to the sites of tissue injury where they exert their therapeutic
activity.
Therapeutic potential of adult stem cells
The plasticity of ASCs is still a controversial issue. Early
reports suggesting that tissue-specific stem cells were able to
transdifferentiate across lineage boundaries were subse-
quently shown to be largely due to technical artifacts.16 The
question is yet open, but we know that some types of adult
stem cells (such as the MSC) have greater plasticity and may
therefore represent good candidates for cell therapeutic
applications.11
The most obvious and potentially best clinical use of
stem cells is to restore (in cell therapy protocols) or replace
(in tissue engineering approaches) tissues that have been
damaged by disease or injury.17 For example, tissues created
using autologous stem cells can be used clinically without
induction of an immune response. Moreover, the use of
these cells avoids the ethical concerns associated with the use
of ESCs. Other problems associated with the clinical use of
ESCs, such as spontaneous differentiation with the risk
of teratoma formation, are avoided. The potential application
of adult stem cells in regenerative medicine is great, as shown
in numerous preclinical and clinical studies.
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Figure 4 | The niche and asymmetric cell division of stem cells. The fate of stem cells is determined by their interaction with their
microenvironment or niche. The niche is composed of other (stromal) cells, extracellular matrix (ECM), and signaling factors, which, in
combination with intrinsic characteristics of stem cells, define their properties and potential. Adult stem cells divide asymmetrically to
produce two kinds of daughter cells. Whereas one remains in the niche as a self-renewing stem cell, the other one becomes a precursor or
progenitor cell, exits the niche, and enters a pathway of proliferation and differentiation, which leads to the formation of a mature cell type.
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Although hematopoietic stem cells have been used for
more than 40 years for hematologic diseases in bone marrow
and cord blood transplantation, the therapeutic use of stem
cells for non-hematologic disorders has been explored only
more recently. A great number of preclinical and clinical
studies have been conducted. At the clinical level, however,
the number of study subjects in most trials is too small, and
controls are often not adequately tested to allow conclusive
assessment of the efficacy of such treatments. Systematic
reviews and meta-analyses of stem cell therapy clinical trials
have shown promising results, however, also demonstrating
the need for adequately powered and well-controlled trials.18
The most common source from which ASCs are isolated is
the bone marrow. The therapeutic results observed for non-
hematologic diseases are believed to be due to MSCs, which
are also present in this tissue.11 More recently, adipose-
derived MSCs have also been used in clinical studies.12 The
three major problems with ESCs—ethical issues, immuno-
logical rejection problems, and the potential of developing
teratomas—are avoided with the use of adult stem cells.
Although the true therapeutic potential of stem cells for non-
hematologic diseases remains to be determined, the mechan-
isms responsible for these effects are becoming increasingly
understood.
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
We are indebted to Conselho Nacional de Desenvolvimento
Cientifico e Tecnologico (CNPq) and Fundacao de Amparo a Pesquisa
do Estado do Rio Grande do Sul for financial support.
REFERENCES
1. Ramalho-Santos M, Willenbring H. On the origin of the term ‘stem cell’.
Cell Stem Cell 2007; 1: 35–38.
2. Till JE, McCulloch EA. Hemopoietic stem cell differentiation. Biochim
Biophys Acta 1980; 605: 431–459.
3. Weissman IL. Stem cells: units of development, units of regeneration,
and units in evolution. Cell 2000; 100: 157–168.
4. Edwards RG. IVF and the history of stem cells. Nature 2001; 413:
349–351.
5. Choumerianou DM, Dimitriou H, Kalmanti M. Stem cells: promises versus
limitations. Tissue Eng Part B Rev 2008; 14: 53–60.
6. Mountford JC. Human embryonic stem cells: origins, characteristics
and potential for regenerative therapy. Transfus Med 2008; 18:
1–12.
7. Rippon HJ, Bishop AE. Embryonic stem cells. Cell Prolif 2004; 37: 23–34.
8. Maherali N, Hochedlinger K. Guidelines and techniques for the
generation of induced pluripotent stem cells. Cell Stem Cell 2008; 3:
595–605.
9. Alison MR, Islam S. Attributes of adult stem cells. J Pathol 2009; 217:
144–160.
10. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells
reside in virtually all post-natal organs and tissues. J Cell Sci 2006; 119:
2204–2213.
11. Meirelles Lda S, Nardi NB. Methodology, biology and clinical applications
of mesenchymal stem cells. Front Biosci 2009; 14: 4281–4298.
12. Beyer Nardi N, da Silva Meirelles L. Mesenchymal stem cells: isolation,
in vitro expansion and characterization. Handb Exp Pharmacol 2006; 174:
249–282.
13. Ott HC, Matthiesen TS, Brechtken J et al. The adult human heart as a
source for stem cells: repair strategies with embryonic-like progenitor
cells. Nat Clin Pract Cardiovasc Med 2007; 4(Suppl 1): S27–S39.
14. Gupta S, Rosenberg ME. Do stem cells exist in the adult kidney?
Am J Nephrol 2008; 28: 607–613.
15. Fuchs E, Tumbar T, Guasch G. Socializing with the neighbors: stem cells
and their niche. Cell 2004; 116: 769–778.
16. Raff M. Adult stem cell plasticity: fact or artifact? Annu Rev Cell Dev Biol
2003; 19: 1–22.
17. Pessina A, Gribaldo L. The key role of adult stem cells: therapeutic
perspectives. Curr Med Res Opin 2006; 22: 2287–2300.
18. Martin-Rendon E, Brunskill SJ, Hyde CJ et al. Autologous bone marrow
stem cells to treat acute myocardial infarction: a systematic review.
Eur Heart J 2008; 29: 1807–1818.
Kidney International Supplements (2011) 1, 63–67 67
PC Chagastelles and NB Nardi: Biology of stem cells m in i rev iew
